
Current Projects
We have a broad and exciting portfolio of diverse research projects from essential basic science to cutting edge clinical trials
OUR PROJECTS

id.DRIVE
Surveillance study of respiratory pathogens in adults hospitalised for SARI across Europe

Coral
A non-interventional, mixed-methods, prospective cohort study to
characterise the real-world implementation, roll out, safety and patient experience of the
long-acting injectable HIV treatment regimen of 2-monthly cabotegravir and rilpivirine

GeoSentinel
GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine (ISTM)

Restorative 303
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection

STRIVE
An open-label dose-escalating study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01 positive, virologically suppressed subjects with chronic HIV infection

Fluent
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Investigate the Safety, Reactogenicity, and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age

Nova 301
A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age

SNAP
Staphylococcus aureus Network Adaptive Platform trial

B-WELL 1
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg_negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus

UKAR
UK Antimicrobial Registry

Define AP3
Define Appendix 3 (VST Therapy)

Odyssey
Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age

MISTRAL
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination

CASCADE
An investigation into the medical and lived experiences of people with recently acquired HIV in Europe and Canada

SUPERNOVA
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)

NEXTCOVE
A randomised, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 administered as a booster dose compared with mRNA-1273.222 in participants aged 12 years and older for the prevention of COVID-19

RECOVERY
Randomised Evaluation of COVID-19 Therapy

PANORAMIC
Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community

RIO
A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART

EuroSIDA
The EuroSIDA network 2005-2009. Clinical and virological outcome of patients with HIV in Europe

DexEnceph
Dexamethasone in Herpes Simplex Virus Encephalitis Randomised Controlled Trial and Non-HSV Cohort Study

VIBRANT
Vaccine Immunity Breakthrough & Re-Infection – ANtibody & T-cells

PrEPaRe
Pre-exposure Prophylaxis Use in People Newly Diagnosed with HIV

IONOE
Improving Outcomes of Necrotising Otitis Externa

TIDE
A multi-centre, randomised controlled, non-inferiority and cost effectiveness trial comparing Polyhexanide and Chlorhexidine with Neomycin to Mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation amongst adult hospital in-patients

HEAL-COVID
HElping Alleviate the Longer-term consequences of COVID-19 (HEAL-COVID)

ISARIC 4C
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) (Scotland)
OUR MEMBERS
Inspiring projects require inspiring teams. We encourage you to find out more about our incredible CIRG professionals.